Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Insights Into Imaging|August 31, 2018
Fasciae of the musculoskeletal system: normal anatomy and MR patterns of involvement in autoimmune diseasesThomas Kirchgesner, Xavier Demondion, Maria Stoenoiu, et al.
Arthritis and Rheumatism|December 1, 2007
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolonePatrick Durez, Jacques Malghem, Adrien Nzeusseu Toukap, et al.
Annals of the Rheumatic Diseases|November 20, 2012
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trialRené Westhovens, Filip De Keyser, Dmytro Rekalov, et al.
BMC Musculoskeletal Disorders|July 9, 2011
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding studyRieke Alten, Juan Gomez-Reino, Patrick Durez, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Lancet (London, England)|July 19, 2008
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialPaul Emery, Ferdinand C Breedveld, Stephen Hall, et al.
Frontiers in Immunology|September 7, 2021
A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid ArthritisFederica Ciregia, Gwenaël Nys, Gaël Cobraiville, et al.
Arthritis Research & Therapy|April 25, 2009
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritisValérie Badot, Christine Galant, Adrien Nzeusseu Toukap, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Insights Into Imaging|August 31, 2018
Fasciae of the musculoskeletal system: normal anatomy and MR patterns of involvement in autoimmune diseasesThomas Kirchgesner, Xavier Demondion, Maria Stoenoiu, et al.
Arthritis and Rheumatism|December 1, 2007
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolonePatrick Durez, Jacques Malghem, Adrien Nzeusseu Toukap, et al.
Annals of the Rheumatic Diseases|November 20, 2012
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trialRené Westhovens, Filip De Keyser, Dmytro Rekalov, et al.
BMC Musculoskeletal Disorders|July 9, 2011
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding studyRieke Alten, Juan Gomez-Reino, Patrick Durez, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Lancet (London, England)|July 19, 2008
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialPaul Emery, Ferdinand C Breedveld, Stephen Hall, et al.
Frontiers in Immunology|September 7, 2021
A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid ArthritisFederica Ciregia, Gwenaël Nys, Gaël Cobraiville, et al.
Arthritis Research & Therapy|April 25, 2009
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritisValérie Badot, Christine Galant, Adrien Nzeusseu Toukap, et al.
Pageof 12